Novartis Inks Chinese mRNA-Therapy Deal for Up to $7.8 Billion
Novartis AG will license a messenger RNA-based autoimmune therapy from China’s Abogen Biosciences, in a deal worth as much as $7.8 billion.
Sourcing & attribution. Newseze provides AI-curated summaries, narrative framing, and editorial analysis. The underlying reporting was contributed by Bloomberg Markets; tap “Open original source” above to read their full reporting and support the contributing newsroom directly.
Newseze's algorithm reads the story and answers your question — calmly, factually, with source attribution. No comments, no flame wars — just answers.
No questions yet. Be the first.
Answers reflect Newseze's editorial framework applied under fair use (17 U.S.C. § 107). Not financial, legal, medical, or tax advice. Hate speech and racial slurs are blocked.
Related stories
Why it mattersFuel is a huge expense for airlines, and even on a good day, jet fuel prices are pretty volatile. Throw in two major wars now effecting energy infrastructure, and fuel prices across the board are higher and higher.
Fuel is a huge expense for airlines, and even on a good day, jet fuel prices are pretty volatile. Throw in two major wars now effecting energy infrastructure, a…
Why it mattersAn art and a science.
Why it mattersBuying a Rolex can take more than money. Here’s how to navigate wait lists, win over dealers and know when to buy secondhand.
Buying a Rolex can take more than money. Here’s how to navigate wait lists, win over dealers and know when to buy secondhand. (Source: Bloomberg)
Why it mattersChina's Epic Wedding Video Microfilms (Video)